Victoza® is a once-daily injectable GLP-1 receptor agonist used to improve blood sugar control in adults and children 10 years and older with type 2 diabetes. It also reduces the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Each Victoza® pen delivers multiple adjustable doses and is designed for ease of use, supporting flexible titration as prescribed. The 3-pack offers a longer supply for added convenience and fewer pharmacy visits.

Features:

• GLP-1 Receptor Agonist Therapy: Helps the body release insulin when needed, reduces glucagon secretion, and slows stomach emptying.

• Cardiovascular Protection: Proven to lower the risk of heart attack, stroke, or cardiovascular death in qualifying adults.

• Adjustable Daily Dosing: Choose from 0.6 mg (starting dose), 1.2 mg (maintenance), or 1.8 mg (maximum dose), as directed by a healthcare provider.

• Prefilled, Multi-Dose Pens: Each pen contains 18 mg of liraglutide and allows daily dosing without mixing or reconstitution.

• Extended Supply: 3 pens per pack—offers up to 45 days of therapy depending on the prescribed daily dose.